Skip to main content
. Author manuscript; available in PMC: 2021 Aug 9.
Published in final edited form as: Nature. 2021 Feb 9;591(7850):451–457. doi: 10.1038/s41586-021-03312-w

Fig. 4. Treatment and pre-exposure prophylaxis with EIDD-2801, a broad-spectrum anti-coronavirus drug, potently inhibit SARS-CoV-2 infection in vivo.

Fig. 4.

a, SARS-CoV-2 titers in the human lung tissue of LoM administered EIDD-2801 (n=8) or vehicle (n=8) 24 h post virus exposure. b, SARS-CoV-2 titers in the human lung tissue of LoM administered EIDD-2801 (n=8) or vehicle (n=8) 48 h post virus exposure. c and d, SARS-CoV-2 titers in the human lung tissue of LoM administered EIDD-2801 (n=8 per experiment, yellow) or control vehicle (Ctrl, n=8 per experiment, blue) at 2 days post-exposure in two independent experiments shown c, separately and d, combined. e, Fold difference in SARS-CoV-2 titers in the human lung tissue of LoM relative to vehicle controls. f, H&E staining and g, immunohistochemical staining for virus nucleoprotein (positive cells, brown) of human lung tissue of LoM administered EIDD-2801 (n=8) or control vehicle (Ctrl, n=8) at 2 days post-exposure (scale bars, 100 um). a-d, Titers were compared with a two-tailed Mann-Whitney U test. Horizontal and vertical lines represent the median and interquartile range respectively. n= number of biologically independent lung tissues analyzed.